<DOC>
	<DOCNO>NCT02821052</DOCNO>
	<brief_summary>This trial conduct Asia . The aim Non-interventional study investigate long-term safety effectiveness Ryzodeg® ( insulin degludec/insulin aspart ) Japanese patient diabetes mellitus require insulin therapy normal clinical practice condition .</brief_summary>
	<brief_title>Post-marketing Surveillance ( Special Use-results Surveillance ) Long-term Use With Ryzodeg®</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Signed consent obtain studyrelated activity ( studyrelated activity procedure relate recording data accord protocol ) The decision initiate treatment commercially available Ryzodeg® make patient/Legally Acceptable Representative ( LAR ) treat physician independently decision include patient study Patients diabetes mellitus require insulin therapy physician decide start treatment Ryzodeg® Male female , age limitation Patients previously treat Ryzodeg® Previous participation study . Participation define give informed consent study Patients history hypersensitivity study product component Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>